原创力文档- 1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
- 2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
2024Deal-making
Roundup
Anin-depthanalysisof2024’sglobaldeal-makingtrends.Thisreport
unpackstheyear’sbiggestmoves,toptherapeuticareas,andstandouttransactionsastrackedbyBiomedtracker.
April2025
The2024averagedealvalueof$83.9millionwasalsoupby6%comparedto2023.
Inthemedtechindustry,financingactivityin
2024alsorampedupinbothdollarvalueand
dealvolume($14.8billionfor350dealsvs$12.2billionfor300dealsin2023).MAactivitywasparticularlystrong,withsevenseparatebillion-dollar-plusacquisitions(thesameas2023),withtotal2024medtechMAspendat$35.9billionfrom57deals,a32%increaseindealvalue,yeta31%declineindealvolumefrom2023.
Thisreportprovidesanoverviewofalliance,
mergerandacquisition,andfinancingdeal
activityacrosstheworldwidebiopharma,
medicaldevice,andinvitrodiagnostics
industriesduring2024asreportedby
Biomedtracker.Theoveralldataispresented
acrossdealtypes,therapyareas,andpaymentorfinancingstructures.Thetopdealsbydollarvalueineachspacearecloselydetailed.Notethatpotentialdealvalue(PDV)isdefinedas
thesumofdisclosedup-frontpayment(s)
plusanyannouncedorreceivedpre-orpost-commercializationmilestonepayment(s).
During2024,thebiopharmaindustryachievedatotalpotentialdealvalue(PDV)of$191.9billionacross690alliances.Althoughdealvolumefor
alliancesdecreasedby28transactionsfrom
2023,theoverallaggregatevaluewas$5billionmoreandtheaveragedealvalue(among
dealswithdisclosedvalues)was$671million,
anincreaseof4%over2023’saveragePDV.
Oncologywasthemostactivetherapeuticareaforpartnering.
Ontheotherhand,the2024biopharmamergerandacquisitiondollarvalueof$79.4billion
reachedonlyabouthalfofthe2023total,yet
2024dealvolumeshowedaslightincrease
overthepreviousyear,with140deals.Four$10
文档评论（0）